“The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance” Dr Gilles Courtemanche, BIOASTER Antimicrobials Program Head is co-author of a scientific publication “MMV688533, a preclinical candidate to cure malaria” @ScienceTM Science Translational Medicine 21 Jul 2021: Vol. 13, Issue 603, eabg6013  https://stm.sciencemag.org/content/13/603/eabg6013...

BIOASTER in collaboration with Cochin Hospital and the REALISM project consortium (study of the pathophysiology of intensive care patients and on biomarkers), has just published...